195 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information 40.
Non-controlling interests ViiV Healthcare The ViiV Healthcare subgroup has a material non-controlling interest.
Summarised financial information in respect of the ViiV Healthcare group is as follows: 2018 2017 2016 m m m Turnover 4,665 4,269 3,527 Profit loss after taxation 560 825 1,249 Other comprehensive income 19 20 36 Total comprehensive income expense 579 845 1,213 2018 2017 m m Non-current assets 2,787 2,736 Current assets 2,643 2,533 Total assets 5,430 5,269 Current liabilities 2,638 2,409 Non-current liabilities 8,895 8,011 Total liabilities 11,533 10,420 Net liabilities 6,103 5,151 2018 2017 2016 m m m Net cash inflow from operating activities 2,212 2,132 1,750 Net cash outflow from investing activities 237 207 326 Net cash outflow from financing activities 1,982 1,820 1,023 Decrease increase in cash and bank overdrafts in the year 7 105 401 The above financial information relates to the ViiV Healthcare group on a stand-alone basis, before the impact of Group-related adjustments, primarily related to the recognition of preferential dividends.
The profit after taxation of 560 million 2017 profit after taxation of 825 million: 2016 loss after taxation of 1,249 million is stated after charging preferential dividends payable to GSK, Shionogi and Pfizer and after a charge of 1,194 million 2017 909 million: 2016 2,186 million for remeasurement of the contingent consideration payable for the acquisition of the former Shionogi-ViiV Healthcare joint venture.
This consideration is expected to be paid over a number of years.
The following amounts attributable to the ViiV Healthcare group are included in GSKs Consolidated statement of comprehensive income, Consolidated statement of changes in equity and Consolidated balance sheet: 2018 2017 2016 m m m Total comprehensive income expense for the year attributable to non-controlling interests 254 187 83 Dividends paid to non-controlling interests 332 316 152 Non-controlling interests in the Consolidated balance sheet 543 476 196 GSK Annual Report 2018 Notes to the financial statements continued 40.
Non-controlling interests continued Consumer Healthcare Joint Venture During 2018, the Group acquired Novartis interest in the Consumer Healthcare Joint Venture to obtain 100% ownership.
The acquisition became unconditional on 3 May 2018 and completed on 1 June 2018.
Summarised financial information in respect of the Consumer Healthcare Joint Venture is as follows: Period ended 3 May 2018 2017 2016 m m m Turnover 2,306 7,003 6,530 Profit after taxation 7 1,211 660 Other comprehensive expense income 79 387 1,640 Total comprehensive expense income 72 824 2,300 2017 m Non-current assets 12,771 Current assets 3,282 Total assets 16,053 Current liabilities 2,675 Non-current liabilities 1,537 Total liabilities 4,212 Net assets 11,841 Period ended 3 May 2018 2017 2016 m m m Net cash inflow from operating activities 65 883 1,496 Net cash inflow outflow from investing activities 442 270 537 Net cash outflow from financing activities 504 1,194 980 Increase decrease in cash and bank overdrafts in the year 3 41 21 The above financial information relates to the Consumer Healthcare Joint Venture on a stand-alone basis, before the impact of Group-related adjustments but after major restructuring charges.
The following amounts attributable to the Consumer Healthcare Joint Venture are included in GSKs Consolidated statement of comprehensive income, Consolidated statement of changes in equity and Consolidated balance sheet: 2018 2017 2016 m m m Total comprehensive income for the year attributable to non-controlling interests 111 296 730 Dividends paid to non-controlling interests 183 420 346 Non-controlling interests in the Consolidated balance sheet 3,631
